重组卡介苗VPM1002BC免疫治疗常规卡介苗治疗后复发的非肌层浸润性膀胱癌的1/2期单臂临床试验:SAKK 06/14
VPM1002BC是基因修饰的牛分枝杆菌卡介苗菌株,可能具有更好的免疫原性和减毒特性。这项1/2期单臂试验纳入常规卡介苗诱导±维持治疗后复发、中高危进展风险的非肌层浸润性膀胱癌患者,评估膀胱内VPM1002BC的疗效、安全性、耐受性和生活质量。主要终点为注册后60周膀胱无复发生存率,40例可分析患者中60周无复发率为49.3%(95%CI 32.1-64.4%),研究达到主要终点,治疗安全且耐受性良好。
要点
- VPM1002BC膀胱内灌注治疗常规卡介苗治疗后复发的非肌层浸润性膀胱癌,60周膀胱无复发率为49.3%(95%CI 32.1-64.4%)。
- 治疗相关1级、2级和3级不良事件分别见于14.3%、54.8%和4.8%的患者,未发生≥4级不良事件。
- 42例患者中2例在诱导期不能耐受5次或以上灌注。
核心结论
- 治疗开始后1年,近半数患者在接受VPM1002BC治疗后保持无复发。
- 研究达到主要终点,该治疗安全且耐受性良好。
- 作者认为结果令人鼓舞,VPM1002BC值得在随机研究中进一步评估。
研究设计与样本
- 1/2期单臂临床试验(NCT02371447)。
- 纳入常规卡介苗诱导±维持治疗后复发、中高危进展风险的非肌层浸润性膀胱癌患者。
- 排除2例不合格患者后,全分析集为40例患者。
- 所有治疗肿瘤均为高级别,27例(67.5%)伴有原位癌。
- 干预为每周6次标准灌注VPM1002BC,随后维持治疗1年;出现复发时停止治疗。
主要发现
- 注册后60周膀胱无复发率为49.3%(95%CI 32.1-64.4%)。
- 注册后2年无复发率为47.4%(95%CI 30.4-62.6%)。
- 注册后3年无复发率为43.7%(95%CI 26.9-59.4%)。
- 3例患者出现进展为肌层浸润性疾病,4例出现转移性疾病。
- 治疗相关1级、2级和3级不良事件分别见于14.3%、54.8%和4.8%的患者,未发生≥4级不良事件。
关键数值与推荐
- 主要终点定义为试验注册后60周膀胱无复发率。
- 样本量基于注册后60周≥30%患者无复发的假设计算。
临床怎么用
- 原文结论指出VPM1002BC值得在非肌层浸润性膀胱癌患者的随机研究中进一步评估。
局限性
- 局限性包括单臂试验设计。
- 局限性包括用于亚组分析的患者数量少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: VPM1002BC is a genetically modified Mycobacterium bovis bacillus Calmette-Guérin (BCG) strain with potentially improved immunogenicity and attenuation. OBJECTIVE: To report on the efficacy, safety, tolerability and quality of life of intravesical VPM1002BC for the treatment of non-muscle-invasive bladder cancer (NMIBC) recurrence after conventional BCG therapy. DESIGN, SETTING, AND PARTICIPANTS: We designed a phase 1/2 single-arm trial (NCT02371447). Patients with recurrent NMIBC after BCG induction ± BCG maintenance therapy and intermediate to high risk for cancer progression were eligible. INTERVENTION: Patients were scheduled for standard treatment of six weekly instillations with VPM1002BC followed by maintenance for 1 yr. Treatment was stopped in cases of recurrence. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was defined as the recurrence-free rate (RFR) in the bladder 60 wk after trial registration. The sample size was calculated based on the assumption that ≥30% of the patients would be without recurrence at 60 wk after registration. RESULTS AND LIMITATIONS: After exclusion of two ineligible patients, 40 patients remained in the full analysis set. All treated tumours were of high grade and 27 patients (67.5%) presented with carcinoma in situ. The recurrence-free rate in the bladder at 60 wk after trial registration was 49.3% (95% confidence interval [CI] 32.1-64.4%) and remained at 47.4% (95% CI 30.4-62.6%] at 2 yr and 43.7% (95% CI 26.9-59.4%) at 3 yr after trial registration. At the same time, progression to muscle-invasive disease had occurred in three patients and metastatic disease in four patients. Treatment-related grade 1, 2, and 3 adverse events (AEs) were observed in 14.3%, 54.8%, and 4.8% of the patients, respectively. No grade ≥4 AEs occurred. Two of the 42 patients did not tolerate five or more instillations during induction. Limitations include the single-arm trial design and the low number of patients for subgroup analysis. CONCLUSIONS: At 1 yr after treatment start, almost half of the patients remained recurrence-free after therapy with VPM100BC. The primary endpoint of the study was met and the therapy is safe and well tolerated. PATIENT SUMMARY: We conducted a trial of VPM100BC, a genetically modified bacillus Calmette-Guérin (BCG) strain for treatment of bladder cancer not invading the bladder muscle. At 1 year after the start of treatment, almost half of the patients with a recurrence after previous conventional BCG were free from non-muscle-invasive bladder cancer (NMIBC). The results are encouraging and VPM1002BC merits further evaluation in randomised studies for patients with NMIBC.
引用
- Rentsch CA, Thalmann GN, Lucca I, et al. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol. 2022. PMID: 35012889. doi:10.1016/j.euo.2021.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。